BG Medicine price target lowered to $7 from $16.50 at Ladenburg Ladenburg reduced its target on BG Medicine after the company announced that it would transition to a marketing-oriented business model and hire a sales team to sell CardioSCORE. The firm thinks the move will provide the company with greater control over CardioSCOPE, but that the move creates more balance sheet risk and may necessitate the introduction of additional partners. The firm reiterates a Buy rating.
News For BGMD From The Last 14 Days
Check below for free stories on BGMD the last two weeks.
Subscribe for More Information